Abstract
The development of vaccines against HIV-1 is currently hindered by incomplete understanding of correlates of protective immunity (1–3). Experiments are necessary to measure immune responses in sufficiently fine detail that specific protective responses can be discerned from those that are irrelevant or harmful. When vaccines are tested as potential therapeutics, it is further necessary to differentiate induced responses from those associated with the infection itself. Measurement of humoral responses to well-defined antigens particularly lends itself to detailed mapping (4). Small synthetic antigens may be used in ELISA or BIAcore assays (5–7). Larger antigens, such as fusion proteins, may require assays with more specificity, because of the possibility of immune-reactive contaminants. A particularly useful technique in this context is immunoblotting, because contaminating antigens are separated away during the electrophoresis step (8,9). In the authors’ laboratory, immunoblots employing fusion proteins of HIV-1 envelope sequences have been successfully used to quantitate new responses post immunization with a vaccine candidate in spite of a substantial baseline response to the whole antigen (10,11). The same technique was used to measure responses against vaccine candidates in small animal models (12,13).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Birx, D. L., Ketter, N., and Fast, P. (1996) HIV vaccine development for treatment and prevention, in Clinical Immunology: Principles and Practice (Rich, R. R. ed.) Mosby, St. Louis, MO, pp. 764–778.
Koff, W. C. and Schultz, A. M. (1996) Progress and challenges toward an AIDS vaccine: brother, can you spare a paradigm? J. Clin. Immunol. 16, 127–133.
Paul, W. E. (1995) Can the immune response control HIV infection? Cell 82, 127-133.
Cason, J. (1994) Strategies for mapping and imitating viral B-cell epitopes. J. Virol. Methods 49, 209–220.
Geysen, H. M., Meloen, R. H., and Barteling, S. J. (1984) Use of peptide synthesis to prove viral antigens for epitopes to a resolution of a single amino acid. Proc. Natl. Acad. Sci. USA 81, 3998–4002.
Hill, H. and Matsen, J. (1983) Enzyme-linked immunosorbent assay and radio-immunoassay in the serologic diagnosis of infectious diseases. J. Infect. Dis. 147, 258–263.
VanCott, T. C, Loomis, L. D., Redfield, R. R., and Birx, D. L. (1992) Real-time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gpl60, of HIV-1. J. Immunol. Methods 146, 163–176.
Stott, D. I. (1989) Immunoblotting and dot blotting. J. Immunol. Methods 119, 153–187.
Towbin, H. and Gordon, J. (1984) Immunoblotting and dot immunoblotting-current status and outlook. J. Immunol. Methods 72, 313–340.
Redfield, R., Birx, D., Ketter, N., Polonis, V., Johnson, S., Davis, C, et al. (1992) Vaccine therapy using rgp 160 in early HIV infection. AIDS. Res. Hum. Retrovir. 8, 1333.
Loomis, L. D., Deal, CD., Kersey, K. S., Burke, D. S., Redfield, R. R., and Birx, D. L. (1995) Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp 160. J. Acquir. Immune Defw. Syndr. 10, 13–26.
Levi, M, Ruden, U., Birx, D., Loomis, L., Redfield, R., Lovgren, K., et al. (1993) Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gpl60 of HIV-1. J. Acquir. Immune Defic. Syndr. 6, 855–864.
Kaminski, R. W., Loomis, L., Levi, M., Amselem, S., Kersey, K., VanCott, T., et al. (1995) HIV peptide and protein antibody responses elicited by immunization with rgp 160 formulated with proteosomes, alum, and/or submicron emulsions. Vacc. Res. 4, 189–206.
Birx, D. L. and Redfield, R. R. (1994) Therapeutic HIV vaccines: concept, current status, and future directions, in Textbook of AIDS Medicine (Broder, S., Merrigan, T. C. Jr., and Bolognesi, D., eds.), Williams and Wilkins, Baltimore, MD, pp. 693–711.
Redfield, R. R., Birx, D. L., Ketter, N., Tramont, E., Polonis, V., Davis, C, et al. (1991) A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gpl60 in patients with early human immunodeficiency virus infection. N. Engl. J. Med. 324, 1677–1684.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Mitchell, M.M., Loomis-Price, L.D. (1999). Quantitative Immunoblotting with Fusion Proteins. In: Michael, N.L., Kim, J.H. (eds) HIV Protocols. Methods in Molecular Medicine™, vol 17. Humana Press. https://doi.org/10.1385/0-89603-369-4:255
Download citation
DOI: https://doi.org/10.1385/0-89603-369-4:255
Publisher Name: Humana Press
Print ISBN: 978-0-89603-369-6
Online ISBN: 978-1-59259-601-0
eBook Packages: Springer Protocols